药品上市后的不良反应监测 ,是关系药品质量和用药安全有效极为重要的环节。国家药品监管局自成立以来 ,不断加强和重视药品不良反应监测工作 ,近两年来 ,积极稳妥地对含苯丙醇胺 (ＰＰＡ)药品制剂采取了停止生产销售 ,对 10多种药品进行了重点监测和再评价 ,分别依法采取了停 Adverse drug reactions monitoring after the listing is a very important part of the relationship between drug quality and drug safety and effectiveness. Since its establishment, the State Drug Administration has continuously strengthened and valued the monitoring of adverse drug reactions. In the past two years, it has actively and steadily stopped producing and selling pharmaceutical preparations containing phenylpropanolamine (PPA), and has focused on more than 10 kinds of medicines Monitoring and re-evaluation, respectively, according to the law to take a stop